+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

bioMerieux SA (BIM) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 64 Pages
  • July 2024
  • GlobalData
  • bioMerieux SA
  • ID: 1290814
bioMerieux SA (BIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

bioMerieux SA (bioMerieux), a subsidiary of Institut Merieux SA, develops, manufactures, and markets in vitro diagnostic solutions for hospital and private laboratories. The company offers diagnostic solutions such as systems, reagents and software for the diagnosis of infectious diseases, cardiovascular diseases and cancers, besides identifying microorganisms in pharmaceuticals, cosmetics, and agri-food products. It offers immunoassays, microbiology products, molecular biology tests and other solutions for clinical applications and industrial microbiological control solutions for the food, biopharmaceutical, and cosmetic industries; veterinary diagnostic laboratories; and blood banks. bioMerieux also provides solutions for the enumeration of bacterial flora, which indicate the quality of food products. The company distributes its products directly and through a network of distributors across the world. bioMerieux is headquartered in Marcy l’Etoile, France.

bioMerieux SA Key Recent Developments

  • Jun 12, 2024: Ameren Missouri doubles renewable energy program
  • May 23, 2024: Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance
  • Apr 09, 2024: bioMerieux Announces First-Quarter 2024 Business Review
  • Oct 26, 2023: bioMerieux : Third-Quarter 2023 Business Review

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • bioMerieux SA - Key Facts
  • bioMerieux SA - Key Employees
  • bioMerieux SA - Key Employee Biographies
  • bioMerieux SA - Major Products and Services
  • bioMerieux SA - History
  • bioMerieux SA - Company Statement
  • bioMerieux SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • bioMerieux SA - Business Description
  • Business Segment: Clinical Applications
  • Overview
  • Performance
  • Business Segment: Industrial Applications
  • Overview
  • Performance
  • Geographical Segment: Americas
  • Performance
  • Geographical Segment: Asia Pacific
  • Performance
  • Geographical Segment: EMEA
  • Performance
  • R&D Overview
  • bioMerieux SA - Corporate Strategy
  • bioMerieux SA - SWOT Analysis
  • SWOT Analysis - Overview
  • bioMerieux SA - Strengths
  • bioMerieux SA - Weaknesses
  • bioMerieux SA - Opportunities
  • bioMerieux SA - Threats
  • bioMerieux SA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • bioMerieux SA, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • bioMerieux SA, Medical Equipment, Deals By Type, 2018 to YTD 2024
  • bioMerieux SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jun 12, 2024: Ameren Missouri doubles renewable energy program
  • May 23, 2024: Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance
  • Apr 09, 2024: bioMerieux Announces First-Quarter 2024 Business Review
  • Oct 26, 2023: bioMerieux : Third-Quarter 2023 Business Review
  • Oct 23, 2023: Oxford Nanopore secures £70m from French diagnostics company
  • Oct 19, 2023: bioMérieux Makes Strategic Investment in Oxford Nanopore
  • Jun 27, 2023: bioMErieux’s Executive Committee evolves: Jennifer Zinn appointed Executive Vice President of Clinical Operations
  • Jun 27, 2023: Jennifer Zinn appointed Executive Vice President of Clinical Operations
  • Apr 27, 2023: bioMerieux ; First-Quarter 2023 Business Review
  • Apr 14, 2023: Oxford Nanopore and BioMerieux to enter into a strategic partnership agreement to develop innovative infectious disease diagnostics
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • bioMerieux SA, Key Facts
  • bioMerieux SA, Key Employees
  • bioMerieux SA, Key Employee Biographies
  • bioMerieux SA, Major Products and Services
  • bioMerieux SA, History
  • bioMerieux SA, Subsidiaries
  • bioMerieux SA, Key Competitors
  • bioMerieux SA, Ratios based on current share price
  • bioMerieux SA, Annual Ratios
  • bioMerieux SA, Interim Ratios
  • bioMerieux SA, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • bioMerieux SA, Medical Equipment, Deals By Type, 2018 to YTD 2024
  • bioMerieux SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • bioMerieux SA, Performance Chart (2019 - 2023)
  • bioMerieux SA, Ratio Charts
  • bioMerieux SA, Medical Equipment, Deals By Year, 2018 to YTD 2024
  • bioMerieux SA, Medical Equipment, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Thermo Fisher Scientific Inc
  • Sysmex Corp
  • Bio-Rad Laboratories Inc
  • Siemens Healthineers AG
  • Ortho Clinical Diagnostics Holdings Plc
  • Eurofins Scientific SE
  • Becton Dickinson and Co
  • Abbott Laboratories
  • OpGen Inc
  • F. Hoffmann-La Roche Ltd
  • Danaher Corp